Evaluating Orthoflavivirus Vaccines with PRNT: Lessons from Yellow Fever Clinical Studies
Open Access
- 10 October 2025
- book chapter
- Published by IntechOpen
Abstract
Flaviviruses represent a major global health concern, with yellow fever virus (YFV) and dengue virus (DENV) among the most studied members of the Orthoflavivirus genus. Transmitted by Aedes mosquitoes, these viruses are responsible for severe disease outbreaks worldwide. While YFV benefits from an effective vaccine, it remains a threat in endemic regions. Dengue, with its four distinct serotypes, continues to complicate vaccine development and disease management. Plaque assays and the plaque reduction neutralization test (PRNT) are key tools for assessing viral replication and immune responses. PRNT50, commonly used in postvaccination studies, quantifies the serum dilution needed to neutralize 50% of the virus, providing insights into vaccine-induced immunity. In contrast, PRNT90, with a higher neutralization threshold, is more appropriate for diagnostics and epidemiological surveillance, offering a stringent measure of past exposure and protection. This chapter focuses on the application of PRNT in yellow fever (YF) vaccine research, highlighting PRNT50 for evaluating immunogenicity and PRNT90 for population-level immunity assessments. We present findings from a core study validating the PRNT assay, followed by clinical research supporting fractional dosing strategies in various populations, including children and immunocompromised individuals. Together, these studies underscore the value of PRNT in optimizing vaccine use and advancing public health strategies against Orthoflavivirus infections.Keywords
This publication has 21 references indexed in Scilit:
- Immunological response to fractional-dose yellow fever vaccine administered during an outbreak in Kinshasa, Democratic Republic of the Congo: results 5 years after vaccination from a prospective cohort studyThe Lancet Infectious Diseases, 2024
- Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trialThe Lancet Infectious Diseases, 2023
- Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trialThe Lancet Infectious Diseases, 2023
- Performance assessment and validation of a plaque reduction neutralization test (PRNT) in support to yellow fever diagnostic and vaccine clinical trialsJournal of Medical Virology, 2023
- Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trialThe Lancet, 2021
- Flavivirus infection—A review of immunopathogenesis, immunological response, and immunodiagnosisVirus Research, 2019
- Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak — Final ReportNew England Journal of Medicine, 2019
- Yellow feverJournal of Clinical Virology, 2015
- Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodiesBiologicals, 2012
- Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster modelVaccine, 2011